Matches in SemOpenAlex for { <https://semopenalex.org/work/W3201548322> ?p ?o ?g. }
Showing items 1 to 77 of
77
with 100 items per page.
- W3201548322 endingPage "iv10" @default.
- W3201548322 startingPage "iv10" @default.
- W3201548322 abstract "Abstract INTRODUCTION Despite advances in treatment modalities, the overall prognosis of GBM remains dismal, particularly for patients with unmethylated MGMT promoter. Thus, alternative treatment strategies are warranted. Our group has previously shown that addition of Sunitinib (SU11248) to standard therapy significantly improved the response of unmethylated MGMT cells through decreased angiogenicity and tumorigenicity. In this phase II trial, we tested for the first time the combination of Sunitinib with RT and Temozolomide in newly diagnosed MGMT unmethylated GBM patients. METHODS Patients with histologically confirmed WHO Grade IV GBM and MS-PCR confirmed unmethylated MGMT promoter, age 18-70, KPS ≥70, life expectancy ≥6 months were eligible. 41 patients treated between 2012 and 2017 were screened, 37 of which were eligible. Patients received 12.5 mg of daily Sunitinib for 7 days, followed by concurrent RT, Temozolomide and 12.5 mg Sunitinib for 6 weeks, then adjuvant Temozolomide x6 cycles. RT and Temozolomide doses were as per standard of care. Primary objective was PFS as assessed by RANO criteria, secondary objectives were OS and safety. RESULTS Median follow-up time was 15 months. Median PFS was 7 months (95%CI, 6.7-7.2) and 6-month PFS was 59.3%. Median OS was 13 months (95%CI, 12.62-13.37) and 2-year OS was 17.8%. Two patients had OS >50 months, with one surviving 71 months. Having received >3 cycles of adjuvant Temozolomide, surgery at progression or age ≤65 significantly predicted for better OS, with hazard ratios of 0.184 (p=0.001), 0.402 (p=0.026) and 10.017 (for age >65, p=0.002) respectively. Grade ≥3 thrombocytopenia occurred in 18.9% of patients, grade ≥3 neutropenia in 10.8% and grade ≥3 thromboembolic events in 13.5%. There were no grade 5 evens. CONCLUSION Addition of Sunitinib to RT and Temozolomide was well tolerated and survival outcomes compared favorably to the current standard of care for GBM patients with unmethylated MGMT promoter status." @default.
- W3201548322 created "2021-09-27" @default.
- W3201548322 creator A5031998230 @default.
- W3201548322 creator A5034231286 @default.
- W3201548322 creator A5052061134 @default.
- W3201548322 creator A5057589857 @default.
- W3201548322 creator A5058602543 @default.
- W3201548322 creator A5083434997 @default.
- W3201548322 creator A5089035835 @default.
- W3201548322 date "2021-09-21" @default.
- W3201548322 modified "2023-10-17" @default.
- W3201548322 title "SYST-08. A phase II trial of concurrent Sunitinib, Temozolomide and Radiation Therapy followed by adjuvant Temozolomide for newly diagnosed Glioblastoma patients with an unmethylated MGMT gene promoter (A01-M121-11A, McG1132)" @default.
- W3201548322 doi "https://doi.org/10.1093/noajnl/vdab112.036" @default.
- W3201548322 hasPublicationYear "2021" @default.
- W3201548322 type Work @default.
- W3201548322 sameAs 3201548322 @default.
- W3201548322 citedByCount "0" @default.
- W3201548322 crossrefType "journal-article" @default.
- W3201548322 hasAuthorship W3201548322A5031998230 @default.
- W3201548322 hasAuthorship W3201548322A5034231286 @default.
- W3201548322 hasAuthorship W3201548322A5052061134 @default.
- W3201548322 hasAuthorship W3201548322A5057589857 @default.
- W3201548322 hasAuthorship W3201548322A5058602543 @default.
- W3201548322 hasAuthorship W3201548322A5083434997 @default.
- W3201548322 hasAuthorship W3201548322A5089035835 @default.
- W3201548322 hasBestOaLocation W32015483221 @default.
- W3201548322 hasConcept C121608353 @default.
- W3201548322 hasConcept C126322002 @default.
- W3201548322 hasConcept C143998085 @default.
- W3201548322 hasConcept C207103383 @default.
- W3201548322 hasConcept C2776694085 @default.
- W3201548322 hasConcept C2777389519 @default.
- W3201548322 hasConcept C2777863537 @default.
- W3201548322 hasConcept C2779490328 @default.
- W3201548322 hasConcept C2780739268 @default.
- W3201548322 hasConcept C31760486 @default.
- W3201548322 hasConcept C44249647 @default.
- W3201548322 hasConcept C509974204 @default.
- W3201548322 hasConcept C535046627 @default.
- W3201548322 hasConcept C71924100 @default.
- W3201548322 hasConceptScore W3201548322C121608353 @default.
- W3201548322 hasConceptScore W3201548322C126322002 @default.
- W3201548322 hasConceptScore W3201548322C143998085 @default.
- W3201548322 hasConceptScore W3201548322C207103383 @default.
- W3201548322 hasConceptScore W3201548322C2776694085 @default.
- W3201548322 hasConceptScore W3201548322C2777389519 @default.
- W3201548322 hasConceptScore W3201548322C2777863537 @default.
- W3201548322 hasConceptScore W3201548322C2779490328 @default.
- W3201548322 hasConceptScore W3201548322C2780739268 @default.
- W3201548322 hasConceptScore W3201548322C31760486 @default.
- W3201548322 hasConceptScore W3201548322C44249647 @default.
- W3201548322 hasConceptScore W3201548322C509974204 @default.
- W3201548322 hasConceptScore W3201548322C535046627 @default.
- W3201548322 hasConceptScore W3201548322C71924100 @default.
- W3201548322 hasIssue "Supplement_4" @default.
- W3201548322 hasLocation W32015483221 @default.
- W3201548322 hasLocation W32015483222 @default.
- W3201548322 hasLocation W32015483223 @default.
- W3201548322 hasOpenAccess W3201548322 @default.
- W3201548322 hasPrimaryLocation W32015483221 @default.
- W3201548322 hasRelatedWork W11687661 @default.
- W3201548322 hasRelatedWork W14450087 @default.
- W3201548322 hasRelatedWork W16180300 @default.
- W3201548322 hasRelatedWork W3582852 @default.
- W3201548322 hasRelatedWork W3706229 @default.
- W3201548322 hasRelatedWork W4669130 @default.
- W3201548322 hasRelatedWork W6095507 @default.
- W3201548322 hasRelatedWork W6779540 @default.
- W3201548322 hasRelatedWork W6961521 @default.
- W3201548322 hasRelatedWork W8337555 @default.
- W3201548322 hasVolume "3" @default.
- W3201548322 isParatext "false" @default.
- W3201548322 isRetracted "false" @default.
- W3201548322 magId "3201548322" @default.
- W3201548322 workType "article" @default.